Diethilde Theil
Overview
Explore the profile of Diethilde Theil including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1500
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Micheli L, Balayssac D, Busserolles J, Dalbos C, Prival L, Richard D, et al.
Toxicology
. 2024 Nov;
510:153998.
PMID: 39551123
Peripheral nervous system (PNS) toxicity assessment in non-clinical safety studies is challenging and relies mostly on histopathological assessment. The present work aims to identify blood-based biomarkers that could detect peripheral...
2.
Theil D, Kuhle J, Brees D, Tritto E, Pognan F, Frieauff W, et al.
Toxicol Pathol
. 2023 Jul;
51(3):135-147.
PMID: 37439009
Branaplam is a splicing modulator previously under development as a therapeutic agent for Spinal Muscular Atrophy Type 1 and Huntington's disease. Branaplam increased the levels of survival motor neuron protein...
3.
Gubser Keller C, Shin Y, Monteys A, Renaud N, Beibel M, Teider N, et al.
Nat Commun
. 2022 Mar;
13(1):1150.
PMID: 35241644
Huntington's Disease (HD) is a progressive neurodegenerative disorder caused by CAG trinucleotide repeat expansions in exon 1 of the huntingtin (HTT) gene. The mutant HTT (mHTT) protein causes neuronal dysfunction,...
4.
Theil D, Valdez R, Darribat K, Doelemeyer A, Sivasankaran R, Hartmann A
Biol Open
. 2021 Sep;
10(10).
PMID: 34528068
Branaplam is a therapeutic agent currently in clinical development for the treatment of infants with type 1 spinal muscular atrophy (SMA). Since preclinical studies showed that branaplam had cell-cycle arrest...
5.
Theil D, Smith P, Huck C, Gilbart Y, Kakarieka A, Leppert D, et al.
Front Immunol
. 2019 Jul;
10:1340.
PMID: 31281311
Ofatumumab is the first, fully human, anti-CD20 monoclonal antibody in Phase 3 development for multiple sclerosis (MS). The study focused on changes in lymphocyte subsets in blood and lymphoid tissues...
6.
Plappert-Helbig U, Libertini S, Frieauff W, Theil D, Martus H
Environ Mol Mutagen
. 2018 Oct;
60(1):4-16.
PMID: 30307065
The phosphorylation of histone H2AX in Serine 139 (gamma-H2AX) marks regions of DNA double strand breaks and contributes to the recruitment of DNA repair factors to the site of DNA...
7.
Pognan F, Mahl J, Papoutsi M, Ledieu D, Raccuglia M, Theil D, et al.
Arch Toxicol
. 2018 Mar;
92(5):1877-1891.
PMID: 29556671
A high incidence of hemangiosarcoma (HSA) was observed in mice treated for 2 years with siponimod, a sphingosine-1-phosphate receptor 1 (S1P1) functional antagonist, while no such tumors were observed in...
8.
Smith P, Schmid C, Zurbruegg S, Jivkov M, Doelemeyer A, Theil D, et al.
J Neuroimmunol
. 2018 Mar;
318:103-113.
PMID: 29530550
Longitudinal brain atrophy quantification is a critical efficacy measurement in multiple sclerosis (MS) clinical trials and the determination of No Evidence of Disease Activity (NEDA). Utilising fingolimod as a clinically...
9.
Guntermann C, Piaia A, Hamel M, Theil D, Rubic-Schneider T, Del Rio-Espinola A, et al.
JCI Insight
. 2017 Mar;
2(5):e91127.
PMID: 28289717
Retinoic-acid-orphan-receptor-C (RORC) is a master regulator of Th17 cells, which are pathogenic in several autoimmune diseases. Genetic deficiency in mice, while preventing autoimmunity, causes early lethality due to metastatic thymic...
10.
Beckmann N, Doelemeyer A, Zurbruegg S, Bigot K, Theil D, Frieauff W, et al.
Neurobiol Aging
. 2016 Jul;
45:50-60.
PMID: 27459925
Currently, several immunotherapies and BACE (Beta Site APP Cleaving Enzyme) inhibitor approaches are being tested in the clinic for the treatment of Alzheimer's disease. A crucial mechanism-related safety concern is...